is beginning a mid-stage clinical trial on its blood cancer drug Clolar in older patients with acute myelogenous leukemia.
The study, dubbed Classic II, is expected to enroll 109 patients age 60 or older. The study is designed to assess the rates of cancer recovery, the duration of remission, disease-free survival time, overall survival, safety and 30-day mortality rates.
"Significant data from investigator-sponsored clinical trials have already been presented regarding the use of Clolar in adult AML and show very encouraging results," said Mark Enyedy, senior vice president and general manager of Genzyme Oncology. "The start of this new clinical study is another important step in our plan to broaden Clolar's label to benefit a larger patient population and address multiple lines of adult AML."
The drug was first cleared in December 2004 to treat children with acute lymphoblastic leukemia.
Shares of Genzyme were down 1.7% to $64.08.